Silo Pharma Advances Psychedelic Patent Portfolio
25 août 2021 08h01 HE
|
Silo Pharma, Inc.
Englewood Cliffs NJ, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today...
Silo Pharma Announces that JV partner Zylo Therapeutics Successfully Completes Initial Inspection for Ketamine Intradermal Research
11 août 2021 08h10 HE
|
Silo Pharma, Inc.
Englewood Cliffs NJ, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB:SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today...
Silo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide Patent
27 juil. 2021 08h08 HE
|
Silo Pharma, Inc.
Central Nervous System Homing Peptide under development to deliver Psychedelics including Psilocybin Englewood Cliffs NJ, July 27, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB:SILO), a...
Silo Pharma To Appear On National Media Broadcast on Psychedelics
21 juil. 2021 10h42 HE
|
Silo Pharma, Inc.
Englewood Cliffs, NJ , July 21, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, has...
Silo Pharma Enters into Sponsored Research Agreement with the University of Maryland, Baltimore
12 juil. 2021 08h08 HE
|
Silo Pharma, Inc.
Englewood Cliffs NJ, July 12, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a development stage biopharmaceutical company, today announced that it has entered into a Scientific Research...
Silo Pharma extends agreement for experimental Rheumatoid Arthritis nanoparticle homing peptide
07 juil. 2021 08h15 HE
|
Silo Pharma, Inc.
Englewood Cliffs NJ, July 07, 2021 (GLOBE NEWSWIRE) -- Silo and University of Maryland, Baltimore extend Option agreement Rheumatoid arthritis (RA) is a chronic disease in which autoimmune attack...
Silo Pharma Announces Collaboration with University California San Francisco to study Psilocybin as an Anti-Inflammatory agent in Parkinson’s and Bipolar Patients
08 juin 2021 08h15 HE
|
Silo Pharma, Inc.
Englewood Cliffs, NJ, June 08, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, is pleased...
Silo Pharma Submits Application for NASDAQ up-listing
25 mai 2021 08h15 HE
|
Silo Pharma, Inc.
Englewood Cliffs, NJ, May 25, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, is pleased...
Silo Pharma announces important milestone. Investigator led study using Psilocybin to treat Parkinson’s disease has been submitted for ethics board review.
13 mai 2021 08h15 HE
|
Silo Pharma, Inc.
Englewood Cliffs, NJ, May 13, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today...
Silo Pharma (SILO) and Zylo Therapeutics, Inc. (ZTI) enter into Joint Venture Agreement to focus on the development of ketamine using ZTI’s Z-pod™ technology for the transdermal time released delivery of therapeutics
28 avr. 2021 08h05 HE
|
Silo Pharma, Inc.
Englewood Cliffs, NJ, April 28, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today...